Advertisement

Fibrotic Skin Diseases

Chapter
  • Dermal fibrosis is excessive scarring of the skin, and is a result of a pathologic wound healing response.

  • There is a wide spectrum of fibrotic skin diseases: scleroderma, nephrogenic fibrosing dermopathy, mixed connective tissue disease, scleromyxedema, scleredema, and eosinophilic fasciitis. Exposures to chemicals or physical agents are also potential causes of fibrotic skin disease.

  • Dermal fibrosis may be driven by immune, autoimmune, and inflammatory mechanisms.

  • The balance of collagen production and degradation by fibroblasts plays a critical role in the pathophysiology of fibrotic processes in the skin.

  • Certain cytokines promote would healing and fibrosis, such as transforming growth factor-β (TGF-β) and interleukin-4 (IL-4), whereas others are antifibrotic, such as interferon-γ (IFN-γ) and transforming growth factor-α (TNF-α).

Keywords

Idiopathic Pulmonary Fibrosis Systemic Sclerosis Connective Tissue Growth Factor Dermal Fibroblast Hypertrophic Scar 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Razzaque MS, Ahmed AR. Collagens, collagen-binding heat shock protein 47 and transforming growth factorbeta 1 are induced in cicatricial pemphigoid: possible role(s) in dermal fibrosis. Cytokine 2002;17:311–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Ricard-Blum S, Hartmann DJ, Esterre P. Monitoring of extracellular matrix metabolism and cross-linking in tissue, serum and urine of patients with chromoblastomycosis, a chronic skin fibrosis. Eur J Clin Invest 1998;28:748–54.PubMedCrossRefGoogle Scholar
  3. 3.
    Zhou L, Askew D, Wu C, Gilliam AC. Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 2007;127:281–92.PubMedCrossRefGoogle Scholar
  4. 4.
    Zhou X, Tan FK, Xiong M, et al. Systemic sclerosis (scleroderma): specific autoantigen genes are selectively overexpressed in scleroderma fibroblasts. J Immunol 2001;167:7126–33.PubMedGoogle Scholar
  5. 5.
    Whitfield ML, Finlay DR, Murray JI, Troyanskaya, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003;100:12319–24.PubMedCrossRefGoogle Scholar
  6. 6.
    Degiorgio-Miller AM, Treharne LJ, McAnulty RJ, et al. Procollagen type I gene expression and cell proliferation are increased in lipodermatosclerosis. Br J Dermatol 2005;152:242–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Herouy Y, May AE, Pornschlegel G, et al. Lipodermatosclerosis is characterized by elevated expression and activation of matrix metalloproteinases: implications for venous ulcer formation. J Invest Dermatol 1998;111:822–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Quatresooz P, Henry F, Paquet P, et al. Deciphering the impaired cytokine cascades in chronic leg ulcers (review). Int J Mol Med 2003;11:411–8.PubMedGoogle Scholar
  9. 9.
    Atamas SP, White B. The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol 2003;15:772–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Atamas SP, White B. Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Growth Factor Rev 2003;14:537–50.PubMedCrossRefGoogle Scholar
  11. 11.
    Atamas SP. Complex cytokine regulation of tissue fibrosis. Life Sci 2002;72:631–43.PubMedCrossRefGoogle Scholar
  12. 12.
    Jelaska A, Strehlow D, Korn JH. Fibroblast heterogeneity in physiological conditions and fibrotic disease. Springer Semin Immunopathol 1999;21:385–95.PubMedGoogle Scholar
  13. 13.
    Tan FK, Arnett FC, Reveille JD, et al. Autoantibodies to fibrillin 1 in systemic sclerosis: ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles. Arthritis Rheum 2000;43:2464–71.PubMedCrossRefGoogle Scholar
  14. 14.
    Zhou X, Tan FK, Milewicz DM, et al. Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-beta pathway to recapitulate the “scleroderma phenotype.” J Immunol 2005;175:4555–60.PubMedGoogle Scholar
  15. 15.
    Kuwana M, Kaburaki J, Medsger TA Jr, et al. An immunodominant epitope on DNA topoisomerase I is conformational in nature: heterogeneity in its recognition by systemic sclerosis sera. Arthritis Rheum 1999;42:1179–88.PubMedCrossRefGoogle Scholar
  16. 16.
    Henry PA, Atamas S P, Yurovsky V V, et al. Diversity and plasticity of the anti-DNA topoisomerase I autoantibody response in scleroderma. Arthritis Rheum 2000;43:2733–42.PubMedCrossRefGoogle Scholar
  17. 17.
    Warrington KJ, Nair U, Carbone LD, et al. Characterisation of the immune response to type I collagen in scleroderma. Arthritis Res Ther 2006;8:R136.PubMedCrossRefGoogle Scholar
  18. 18.
    Hu PQ, Oppenheim JJ, Medsger TA Jr, et al. T cell lines from systemic sclerosis patients and healthy controls recognize multiple epitopes on DNA topoisomerase I. J Autoimmun 2006;26:258–67.PubMedCrossRefGoogle Scholar
  19. 19.
    Marie I, Cordel N, Lenormand B, et al. Clonal T cells in the blood of patients with systemic sclerosis. Arch Dermatol 2005;141:88–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Sakkas LI, Xu B, Artlett CM, et al. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002;168:3649–59.PubMedGoogle Scholar
  21. 21.
    Skert C, Patriarca F, Sperotto A, et al. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome. Haematologica 2006;91:258–61.PubMedGoogle Scholar
  22. 22.
    Schaffer JV, McNiff JM, Seropian S, et al. Lichen sclerosus and eosinophilic fasciitis as manifesta-tions of chronic graft-versus-host disease: expanding the sclerodermoid spectrum. J Am Acad Dermatol 2005;53:591–601.PubMedCrossRefGoogle Scholar
  23. 23.
    Zhang Y, McCormick LL, Desai SR, et al. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 2002;168:3088– 98.PubMedGoogle Scholar
  24. 24.
    Kaplan DH, Anderson BE, McNiff JM, et al. Target antigens determine graft-versus-host disease pheno-type. J Immunol 2004;173:5467–75.PubMedGoogle Scholar
  25. 25.
    Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004;50:2660–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 2004;30:569–77.PubMedCrossRefGoogle Scholar
  27. 27.
    Tredget EE, Yang L, Delehanty M, et al. Polarized Th2 cytokine production in patients with hypertrophic scar following thermal injury. J Interferon Cytokine Res 2006;26:179–89.PubMedCrossRefGoogle Scholar
  28. 28.
    Liu W, Ding I, Chen K, et al. Interleukin 1beta (IL1B) signaling is a critical component of radiationinduced skin fibrosis. Radiat Res 2006;165:181–91.PubMedCrossRefGoogle Scholar
  29. 29.
    Martin M, Lefaix JL, Pinton P, et al. Temporal modulation of TGF-beta 1 and beta-actin gene expression in pig skin and muscular fibrosis after ionizing radiation. Radiat Res 1993;134:63–70.PubMedCrossRefGoogle Scholar
  30. 30.
    Lafuma C, El Nabout RA, Crechet F, et al. Expression of 72-kDa gelatinase (MMP-2), collagenase (MMP1), and tissue metalloproteinase inhibitor (TIMP) in primary pig skin fibroblast cultures derived from radiation-induced skin fibrosis. J Invest Dermatol 1994;102:945–50.PubMedCrossRefGoogle Scholar
  31. 31.
    Flanders KC, Sullivan CD, Fujii M, et al. Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J Pathol 2002;160:1057–68.PubMedGoogle Scholar
  32. 32.
    Saito E, Fujimoto M, Hasegawa M, et al. CD19dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002;109:1453–62.PubMedGoogle Scholar
  33. 33.
    Muryoi T, Kasturi KN, Kafina MJ, et al. Antitopoisomerase I monoclonal autoantibodies from scleroderma patients and tight skin mouse interact with similar epitopes. J Exp Med 1992;175:1103–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Wang HW, Tedla N, Hunt JE, et al. Mast cell accumulation and cytokine expression in the tight skin mouse model of scleroderma. Exp Dermatol 2005;14:295–302.PubMedCrossRefGoogle Scholar
  35. 35.
    Kodera T, McGaha TL, Phelps R, et al. Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-beta production by fibroblasts. Proc Natl Acad Sci USA 2002;99:3800–5.PubMedCrossRefGoogle Scholar
  36. 36.
    McGaha TL, Le M, Kodera T, et al. Molecular mechanisms of interleukin-4-induced up-regulation of type I collagen gene expression in murine fibroblasts. Arthritis Rheum 2003;48:2275–84.PubMedCrossRefGoogle Scholar
  37. 37.
    McGaha T, Saito S, Phelps RG, et al. Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R alpha and transforming growth factor-beta genes. J Invest Dermatol 2001;116:136–43.PubMedCrossRefGoogle Scholar
  38. 38.
    Christner PJ, Hitraya EG, Peters J, et al. Transcriptional activation of the alpha1(I) procollagen gene and upregulation of alpha1(I) and alpha1(III) procollagen messenger RNA in dermal fibroblasts from tight skin 2 mice. Arthritis Rheum 1998;41:2132–42.PubMedCrossRefGoogle Scholar
  39. 39.
    Christner PJ, Peters J, Hawkins D, et al. The tight skin 2 mouse. An animal model of scleroderma displaying cutaneous fibrosis and mononuclear cell infiltration Arthritis Rheum 1995;38:1791–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Gentiletti J, McCloskey LJ, Artlett CM, et al. Demonstration of autoimmunity in the tight skin2 mouse: a model for scleroderma. J Immunol 2005;175:2418–26.PubMedGoogle Scholar
  41. 41.
    Wallace VA, Kondo S, Kono T, et al. A role for CD4+ T cells in the pathogenesis of skin fibrosis in tight skin mice. Eur J Immunol 1994;24:1463–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Wooley PH, Sud S, Langendorfer A, et al. T cells infiltrating the skin of Tsk2 scleroderma-like mice exhibit T cell receptor bias. Autoimmunity 1998;27:91–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Sugerman PB, Faber SB, Willis LM, et al. Kinetics of gene expression in murine cutaneous graft-versushost disease. Am J Pathol 2004;164:2189–202.PubMedGoogle Scholar
  44. 44.
    Yamamoto T, Nishioka K. Possible role of apoptosis in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2004;122:44–50.PubMedCrossRefGoogle Scholar
  45. 45.
    Yamamoto T, Nishioka K. Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2003;121:510–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Takagawa S, Lakos G, Mori Y, et al. Sustained activation of fibroblast transforming growth factor-beta/ Smad signaling in a murine model of scleroderma. J Invest Dermatol 2003;121:41–50.PubMedCrossRefGoogle Scholar
  47. 47.
    Lakos G, Takagawa S, Chen SJ, et al. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 2004;165:203–17.PubMedGoogle Scholar
  48. 48.
    Atamas SP. Alternative splice variants of cytokines: making a list. Life Sci 1997;61:1105–12.PubMedCrossRefGoogle Scholar
  49. 49.
    Postlethwaite AE, Shigemitsu H, Kanangat S. Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol 2004;16:733–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Chesney J, Metz C, Stavitsky AB, et al. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J Immunol 1998;160:419–25.PubMedGoogle Scholar
  51. 51.
    Yang L, Scott PG, Dodd C, et al. Identification of fibrocytes in postburn hypertrophic scar. Wound Repair Regen 2005;13:398–404.PubMedCrossRefGoogle Scholar
  52. 52.
    Ishii G, Sangai T, Sugiyama K, et al. In vivo characterization of bone marrow-derived fibroblasts recruited into fibrotic lesions. Stem Cells 2005;23:699–706.PubMedCrossRefGoogle Scholar
  53. 53.
    Yamamoto T, Eckes B, Krieg T. High expression and autoinduction of monocyte chemoattractant protein-1 in scleroderma fibroblasts. Eur J Immunol 2001;31:2936–41.PubMedCrossRefGoogle Scholar
  54. 54.
    Yamamoto T, Eckes B, Mauch C, et al. Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop. J Immunol 2000;164:6174–9.PubMedGoogle Scholar
  55. 55.
    Asano Y, Ihn H, Yamane K, et al. Increased expression of integrin alphavbeta5 induces the myofibroblastic differentiation of dermal fibroblasts. Am J Pathol 2006;168:499–510.PubMedCrossRefGoogle Scholar
  56. 56.
    Asano Y, Ihn H, Yamane K, et al. Increased expression of integrin alpha(v)beta3 contributes to the establishment of autocrine TGF-beta signaling in scleroderma fibroblasts. J Immunol 2005;175:7708–18.PubMedGoogle Scholar
  57. 57.
    Asano Y, Ihn H, Yamane K, et al. Impaired Smad7– Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J Clin Invest 2004;113:253–64.PubMedGoogle Scholar
  58. 58.
    Jelaska A, Korn JH. Role of apoptosis and transforming growth factor beta1 in fibroblast selection and activation in systemic sclerosis. Arthritis Rheum 2000;4310:2230–9.CrossRefGoogle Scholar
  59. 59.
    Moulin V, Larochelle S, Langlois C, et al. Normal skin wound and hypertrophic scar myofibroblasts have differential responses to apoptotic inductors. J Cell Physiol 2004;198:350–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Chizzolini C, Rezzonico R, Ribbens C, et al. Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. Arthritis Rheum 1998;41:2039–47.PubMedCrossRefGoogle Scholar
  61. 61.
    Chizzolini C, Parel Y, De Luca C, et al. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum 2003;48:2593–604.PubMedCrossRefGoogle Scholar
  62. 62.
    Ong C, Wong C, Roberts CR, et al. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol 1998;28:2619–29.PubMedCrossRefGoogle Scholar
  63. 63.
    Atamas SP. FCP (http://fibro.biobitfield.com/fcp. php): a bioinformatic tool assisting in PubMed searches for literature on fibrosis-related cytokines. Arthritis Rheum 2003;48:2083–4.PubMedCrossRefGoogle Scholar
  64. 64.
    Atamas SP, Luzina IG, Dai H, et al. Synergy between CD40 ligation and IL-4 on fibroblast proliferation involves IL-4 receptor signaling. J Immunol 2002;168:1139–45.PubMedGoogle Scholar
  65. 65.
    Atamas SP, Yurovsky V V, Wise R, et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999;42:1168–78.PubMedCrossRefGoogle Scholar
  66. 66.
    Rezzonico R, Burger D, Dayer JM. Direct contact between T lymphocytes and human dermal fibroblasts or synoviocytes down-regulates types I and III collagen production via cell-associated cytokines. J Biol Chem 1998;273:18720–8.PubMedCrossRefGoogle Scholar
  67. 67.
    De Palma R, Del Galdo F, Lupoli S, et al. Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin. Clin Exp Immunol 2006;144:169–76.PubMedCrossRefGoogle Scholar
  68. 68.
    Hasegawa M, Hamaguchi Y, Yanaba K, et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 2006;169:954–66.PubMedCrossRefGoogle Scholar
  69. 69.
    Sato S, Hasegawa M, Fujimoto M, et al. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000;165:6635–43.PubMedGoogle Scholar
  70. 70.
    Yamamoto T, Hartmann K, Eckes B, et al. Role of stem cell factor and monocyte chemoattractant protein-1 in the interaction between fibroblasts and mast cells in fibrosis. J Dermatol Sci 2001;26:106–11.PubMedCrossRefGoogle Scholar
  71. 71.
    Trautmann A, Krohne G, Brocker EB, et al. Human mast cells augment fibroblast proliferation by heterotypic cell-cell adhesion and action of IL-4. J Immunol 1998;160:5053–7.PubMedGoogle Scholar
  72. 72.
    Kakizoe E, Shiota N, Tanabe Y, et al. Isoform-selective upregulation of mast cell chymase in the development of skin fibrosis in scleroderma model mice. J Invest Dermatol 2001;116:118–23.PubMedCrossRefGoogle Scholar
  73. 73.
    Abe M, Kurosawa M, Ishikawa O, et al. Effect of mast cell-derived mediators and mast cell-related neutral proteases on human dermal fibroblast proliferation and type I collagen production. J Allergy Clin Immunol 2000;106:S78–84.PubMedCrossRefGoogle Scholar
  74. 74.
    Shephard P, Martin G, Smola-Hess S, et al. Myofibroblast differentiation is induced in keratinocyte-fibroblast co-cultures and is antagonistically regulated by endogenous transforming growth factor-beta and interleukin-1. Am J Pathol 2004;164:2055–66.PubMedGoogle Scholar
  75. 75.
    Bellemare J, Roberge CJ, Bergeron D, et al. Epidermis promotes dermal fibrosis: role in the pathogenesis of hypertrophic scars. J Pathol 2005;206:1–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Funayama E, Chodon T, Oyama A, et al. Keratinocytes promote proliferation and inhibit apoptosis of the under-lying fibroblasts: an important role in the pathogenesis of keloid. J Invest Dermatol 2003;121:1326–31.PubMedCrossRefGoogle Scholar
  77. 77.
    Khoo YT, Ong CT, Mukhopadhyay A, et al. Upregulation of secretory connective tissue growth factor (CTGF) in keratinocyte-fibroblast coculture contributes to keloid pathogenesis. J Cell Physiol 2006;208:336–43.PubMedCrossRefGoogle Scholar
  78. 78.
    Sivan V, Vozenin-Brotons MC, Tricaud Y, et al. Altered proliferation and differentiation of human epidermis in cases of skin fibrosis after radiotherapy. Int J Radiat Oncol Biol Phys 2002;53:385–93.PubMedGoogle Scholar
  79. 79.
    Gharaee-Kermani M, Phan SH. Role of cytokines and cytokine therapy in wound healing and fibrotic diseases. Curr Pharm Des 2001;7:1083–103.PubMedCrossRefGoogle Scholar
  80. 80.
    McCormick LL, Zhang Y, Tootell E, et al. AntiTGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999;163:5693–9.PubMedGoogle Scholar
  81. 81.
    Zhang Y, McCormick LL, Gilliam AC. Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 2003;21:713–9.CrossRefGoogle Scholar
  82. 82.
    Santiago B, Gutierrez-Canas I, Dotor J, et al. Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol 2005;125:450–5.PubMedCrossRefGoogle Scholar
  83. 83.
    Wang XJ, Han G, Owens P, et al. Role of TGFbetamediated inflammation in cutaneous wound healing. J Invest Dermatol 2006;126:112–7.Google Scholar
  84. 84.
    Hakkinen L, Koivisto L, Gardner H, et al. Increased expression of beta6–integrin in skin leads to spontaneous development of chronic wounds. Am J Pathol 2004;164:229–42.PubMedGoogle Scholar
  85. 85.
    Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 2003;48:1964–78.PubMedCrossRefGoogle Scholar
  86. 86.
    Gao Z, Wang Z, Shi Y, et al. Modulation of collagen synthesis in keloid fibroblasts by silencing Smad2 with siRNA. Plast Reconstr Surg 2006;118:1328–37.PubMedCrossRefGoogle Scholar
  87. 87.
    Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007;56:311–22.PubMedCrossRefGoogle Scholar
  88. 88.
    Chen SJ, Ning H, Ishida W, et al. The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem 2006;281:21183–97.PubMedCrossRefGoogle Scholar
  89. 89.
    Dong C, Zhu S, Wang T, et al. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci USA 2002;99:3908–13.PubMedCrossRefGoogle Scholar
  90. 90.
    Leask A, Denton CP, Abraham DJ. Insights into the molecular mechanism of chronic fibrosis: the role of connective tissue growth factor in scleroderma. J Invest Dermatol 2004;122:1–6.PubMedCrossRefGoogle Scholar
  91. 91.
    Holmes A, Abraham DJ, Chen Y, et al. Constitutive connective tissue growth factor expression in scleroderma fibroblasts is dependent on Sp1. J Biol Chem 2003;278:41728–33.PubMedCrossRefGoogle Scholar
  92. 92.
    Mori T, Kawara S, Shinozaki M, et al. J Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model. Cell Physiol 1999;181:153–9.CrossRefGoogle Scholar
  93. 93.
    Jinnin M, Ihn H, Yamane K, et al. Interleukin-13 stimulates the transcription of the human alpha2(I) collagen gene in human dermal fibroblasts. J Biol Chem 2004;279:41783–91.PubMedCrossRefGoogle Scholar
  94. 94.
    Granel B, Chevillard C, Allanore Y, et al. Evaluation of interleukin 13 polymorphisms in systemic sclerosis. Immunogenetics 2006;58:693–9.PubMedCrossRefGoogle Scholar
  95. 95.
    Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996;271:17779–84.PubMedCrossRefGoogle Scholar
  96. 96.
    Carulli MT, Ong VH, Ponticos M, et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibrob-last differentiation. Arthritis Rheum 2005;52:3772–82.PubMedCrossRefGoogle Scholar
  97. 97.
    Distler JH, Jungel A, Caretto D, et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum 2006;54:214–25.PubMedCrossRefGoogle Scholar
  98. 98.
    Distler O, Pap T, Kowal-Bielecka O, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001;44:2665–78.PubMedCrossRefGoogle Scholar
  99. 99.
    Luzina IG, Atamas SP, Wise R, et al. Gene expression in bronchoalveolar lavage cells from scleroderma patients. Am J Respir Cell Mol Biol 2002;26:549–57.PubMedGoogle Scholar
  100. 100.
    Luzina IG, Highsmith K, Pochetuhen K, et al. PKCalpha mediates CCL18–stimulated collagen production in pulmonary fibroblasts. Am J Respir Cell Mol Biol 2006;35:298–305.PubMedCrossRefGoogle Scholar
  101. 101.
    Luzina IG, Tsymbalyuk N, Choi J, et al. CCL18– stimulated upregulation of collagen production in lung fibroblasts requires Sp1 signaling and basal Smad3 activity. J Cell Physiol 2006;206:221–8.PubMedCrossRefGoogle Scholar
  102. 102.
    Atamas SP, Luzina IG, Choi J, et al. Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts. Am J Respir Cell Mol Biol 2003;29:743–9.PubMedCrossRefGoogle Scholar
  103. 103.
    Luzina IG, Papadimitriou JC, Anderson R, et al. Induction of prolonged infiltration of T lymphocytes and transient T lymphocyte- dependent collagen deposition in mouse lungs following adenoviral gene transfer of CCL18. Arthritis Rheum 2006;54:2643–55.PubMedCrossRefGoogle Scholar
  104. 104.
    Mori R, Kondo T, Ohshima T, et al. Accelerated wound healing in tumor necrosis factor receptor p55–deficient mice with reduced leukocyte infiltration. FASEB J 2002;16:963–74.PubMedCrossRefGoogle Scholar
  105. 105.
    Lee RH, Efron DT, Tantry U, et al. Inhibition of tumor necrosis factor-alpha attenuates wound breaking strength in rats. Wound Repair Regen 2000;8:547–53.PubMedCrossRefGoogle Scholar
  106. 106.
    Kouba DJ, Nakano H, Nishiyama T, et al. Tumor necrosis factor-alpha induces distinctive NF-kappa B signaling within human dermal fibroblasts. J Biol Chem 2001;276:6214–24.PubMedCrossRefGoogle Scholar
  107. 107.
    Yamane K, Ihn H, Asano Y, et al. Antagonistic effects of TNF-alpha on TGF-beta signaling through down-regulation of TGF-beta receptor type II in human dermal fibroblasts. J Immunol 2003;171:3855–62.PubMedGoogle Scholar
  108. 108.
    Verrecchia F, Pessah M, Atfi A, et al. Tumor necrosis factor-alpha inhibits transforming growth factor-beta /Smad signaling in human dermal fibroblasts via AP-1 activation. J Biol Chem 2000;275:30226–31.PubMedCrossRefGoogle Scholar
  109. 109.
    Abraham DJ, Shiwen X, Black CM, et al. Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem 2000;275:15220–5.PubMedCrossRefGoogle Scholar
  110. 110.
    Ghosh AK, Bhattacharyya S, Mori Y, et al. Inhibition of collagen gene expression by interferon-gamma: novel role of the CCAAT/enhancer binding protein beta (C/EBPbeta). J Cell Physiol 2006;207:251–60.PubMedCrossRefGoogle Scholar
  111. 111.
    Ghosh AK, Yuan W, Mori Y, et al. Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-beta. Integration at the level of p300/CBP transcriptional coactivators. J Biol Chem 2001;276:11041–8.PubMedCrossRefGoogle Scholar
  112. 112.
    Higashi K, Inagaki Y, Fujimori K, et al. Interferongamma interferes with transforming growth factorbeta signaling through direct interaction of YB-1 with Smad3. J Biol Chem 2003;278:43470–9.PubMedCrossRefGoogle Scholar
  113. 113.
    Ishida Y, Kondo T, Takayasu T, et al. The essential involvement of cross-talk between IFN-gamma and TGF-beta in the skin wound-healing process. J Immunol 2004;172:1848–55.PubMedGoogle Scholar
  114. 114.
    Hasegawa T, Nakao A, Sumiyoshi K, et al. IFNgamma fails to antagonize fibrotic effect of TGF-beta on keloid-derived dermal fibroblasts. J Dermatol Sci 2003;32:19–24.PubMedCrossRefGoogle Scholar
  115. 115.
    Hunzelmann N, Anders S, Fierlbeck G, et al. Doubleblind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma. J Am Acad Dermatol 1997;36:433–5.PubMedCrossRefGoogle Scholar
  116. 116.
    Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125–33.PubMedCrossRefGoogle Scholar
  117. 117.
    Bolinger AM, Taeubel MA. Recombinant interferon gamma for treatment of chronic granulo-matous disease and other disorders. Clin Pharm 1992;11:834–50.PubMedGoogle Scholar
  118. 118.
    Virtual Round Table on ten leading questions for network research. Eur Phys J [B] 2004;38:143–5.Google Scholar
  119. 119.
    Feldmann M, Bondeson J, Brennan FM, et al. The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards? Ann Rheum Dis 1999;58:I27–31.PubMedCrossRefGoogle Scholar
  120. 120.
    Denton CP, Merkel PA, Furst DE, et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007;56:323–33.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2008

Authors and Affiliations

  1. 1.Department of MedicineUniversity of Maryland School of MedicineBaltimoreUSA

Personalised recommendations